

2025. Pneumococcal vaccination

RCT/Pneumococcal vaccine/IBD

Multicenter, randomized open-label study in France. IBD patients on biologic therapy were randomized to an intensified (PCV13/PCV13/PPSV23) or standard (PCV13/PPSV23) regimen.

Primary endpoint: Vaccine response at month 5 defined as antibody titers $>1 \mu\text{g/mL}$ for at least 9 of 13 serotypes in ELISA.

Results: N=104

- At 5 months vaccine response was higher in the intensified group vs standard (53.2% vs 27.1%, $p=0.009$) measured by ELISA.
- Measured by opsonophagocytic assays [OPA]) responses remained higher in the intensified group at month 12, 18 and 36.
- Reduced responses were associated with anti-TNF therapy, combo therapy and Crohn's disease.

Conclusion:

Intensified vaccination significantly enhances and sustains immune response over 36 months, particularly benefiting patients with CD on anti-TNF therapy.

Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study

Vaccine response at 5 months

